We have updated the Onselex Pharmaceuticals corporate presentation, including a supplemental IPO Roadmap at the end of the deck.

The main presentation highlights ONX-1006:

• Established drug, transformed delivery
• Compelling evidence: Strong antitumor efficacy and excellent safety — Slides 5 and 6
• Sustained and extended dosing — Slide 7

Our near-term objective remains advancing ONX-1006 from a robust preclinical development package into human clinical evaluation for Stage IV pancreatic cancer.